Pfizer could be just a few months away from getting FDA approval for its JAK1 inhibitor abrocitinib in atopic dermatitis, a drug that CEO Albert Bourla believes hasn’t been given the credit it ...

Pfizer has reported new data with abrocitinib, a follow-up to its JAK inhibitor Xeljanz, which is facing increased competition from new drugs in the class. Xeljanz (tofacitinib) is approved to ...

Pfizer and Glenmark Pharmaceuticals Ltd. have partnered to launch abrocitinib, an oral advanced systemic treatment for moderate‐to‐severe atopic dermatitis (AD), in India. Developed by Pfizer ...